Human Papillomavirus Vaccine Effective in Preventing Cervical Cancer Lesions
A new HPV vaccine, which works by creating antibodies to HPV-16 and HPV-18, as well as two other HPV types, was recently approved by the US Food and Drug Administration (FDA) for females aged 11-26 to prevent infection from HPV. The vaccine, known as Gardasil®, is manufactured by Merck & Co., Inc., and is currently the only HPV vaccine approved by the FDA.
The results of a large clinical phase 3 trial published in the May 10, 2007 issue of the New England Journal of Medicine indicate that this HPV vaccine is highly effective in preventing high-grade cervical lesions, which include precancerous and cancerous lesions.
About the Study
This trial, called Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) II, was conducted at 90 study sites in 13 countries, and funded by Merck. A total of 12,167 women aged 15-26 participated in the double-blind, placebo-controlled study. Each participant was randomly assigned to receive either the vaccine or a placebo at day 1, month 2, and month 6. After treatment, participants were followed for an average of three years, with visits scheduled for 1 and 6 months after the final injection, and then in months 24, 36, and 48.
The purpose of the trial was to determine whether the HPV vaccine would prevent the development of high-grade cervical lesions, including severe cervical intraepithelial neoplasia (a kind of precancerous cell abnormality indicating the presence of HPV infection), adenocarcinoma
For the 10,565 women who had never been exposed to the virus and who received all three vaccines according to protocol, researchers found that the vaccine was highly (98%) effective in preventing high-grade cervical lesions. However, the effectiveness of the vaccine dropped to 44% when the researchers considered all women who were initially enrolled in the study, some of whom did not complete the three-vaccine protocol or were already infected with HPV.
How Does This Affect You?
This study confirms findings from a previous large-scale trial, which found that the HPV vaccine was highly effective in preventing cervical precancers and
Overall, both of these large-scale studies seem to indicate that the vaccine can be effective in preventing precancerous and cancerous cervical lesions related to HPV-16 and HPV-18. However, the vaccine can only be expected to work well for women who adhere to the vaccine protocol and have not been previously infected with HPV. This is important, since many women who obtain the vaccine outside of a research study, will not receive all three doses and will already have undiagnosed infection. Furthermore, the vaccine offers no protection for women infected with HPV types other than the four included in the vaccine.
As cervical cancer is one of the most common types of cancer in women, and results in approximately 250,000 deaths worldwide each year, preventive treatment to protect against this disease is highly desirable. However, the vaccine has been the source of controversy among many groups—including policymakers, clinicians, religious groups, and parents—who are divided on when and whether this should be administered to young girls, and whether it should be voluntary or mandatory.
For women who do choose to be immunized with this vaccine, researchers agree that it will be important to continue with other types of cervical cancer screening, such as regular
National Cancer Institute
Human Papillomavirus Vaccines: Questions and Answers
US Centers for Disease Control
HPV and HPV Vaccine
The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med . 2007;356(19):1915-27.
Sawaya GF, Smith-McCune K. HPV vaccination—more answers, more questions. N Engl J Med . 2007;356:1991-1993.
Last reviewed June 2007 by
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.